Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.

Autor:in

Weber, Tobias; Bötticher, Benedikt; Arndt, Michaela A E; Mier, Walter; Sauter, Max; Exner, Evelyn; Keller, Armin; Krämer, Susanne; Leotta, Karin; Wischnjow, Artjom; Grosse-Hovest, Ludger; Strumberg, Dirk; Jäger, Dirk; Gröne, Hermann-Josef; Haberkorn, Uwe; Brem, Gottfried; Krauss, Jürgen

Schlagwörter

Animals; Antibodies, Bispecificimmunologypharmacokineticspharmacologytoxicity; Antibodies, Monoclonal, Humanizedimmunologypharmacokineticspharmacologytoxicity; Burkitt Lymphomaimmunologymetabolismpathologyradiotherapy; Cell Line, Tumor; Female; Forkhead Transcription Factorsdeficiencygenetics; Homeodomain Proteinsgeneticsmetabolism; Humans; Immunoconjugatespharmacokineticspharmacologytoxicity; Immunoglobulins, Intravenouspharmacology; Interleukin Receptor Common gamma Subunitdeficiencygenetics; Lutetiumpharmacokineticspharmacologytoxicity; Lymphoma, Mantle-Cellimmunologymetabolismpathologyradiotherapy; Mice, Inbred NOD; Mice, Knockout; Mice, Nude; Radioimmunotherapyadverse effectsmethods; Radioisotopespharmacokineticspharmacologytoxicity; Rituximabpharmacology; Sialic Acid Binding Ig-like Lectin 2immunologymetabolism; Tissue Distribution; Xenograft Model Antitumor Assays

ISSN/eISSN

0304-3835 -

WoS ID

WOS:000385332400003